Theravance Biopharma (NASDAQ:TBPH) Releases Quarterly Earnings Results, Misses Expectations By $0.26 EPS

Theravance Biopharma (NASDAQ:TBPH) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26), Zacks reports. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%.

Theravance Biopharma Stock Up 1.2 %

NASDAQ TBPH traded up $0.11 during trading hours on Wednesday, hitting $9.08. 276,927 shares of the company were exchanged, compared to its average volume of 205,984. The firm has a market cap of $446.50 million, a price-to-earnings ratio of -8.99 and a beta of 0.21. The company has a 50 day moving average of $9.36 and a two-hundred day moving average of $8.91. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.90.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.